Navigation Links
Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
Date:1/25/2008

OSAKA, Japan and PALO ALTO, Calif., Jan. 25 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) and Affymax, Inc. (Nasdaq: AFFY) today announced that Takeda has dosed the first patient in the United States in a clinical trial of the investigational new drug, Hematide(TM), for the treatment of anemia in cancer patients undergoing chemotherapy.

Under the terms of the 2006 collaboration, Takeda and Affymax are jointly developing Hematide, and Affymax is now conducting Phase 3 studies for the treatment of anemia in chronic renal failure patients in the U.S. and Europe.

"We are pleased to begin the first U.S.-based clinical trial of Hematide in chemotherapy induced anemia (CIA)," said Masaomi Miyamoto, Ph.D., general manager of Takeda's pharmaceutical development division. "We will actively conduct development activities together with Affymax in order to bring this novel, potential treatment option to patients with anemia and physicians who treat them."

Arlene M. Morris, president and chief executive officer of Affymax, added "We look forward to continuing to support Takeda's efforts in the clinical development of Hematide in chemotherapy induced anemia. We are pleased with the data generated to date from our trial in CIA in Europe, which was completed last year and look forward to additional data in this indication from this first U.S.-based trial."

The multicenter, open-label, repeat dose clinical trial in CIA will enroll approximately 100 non-small cell lung cancer, prostate or breast cancer patients who have relapsed or progressed after previous treatment and who are anemic and receiving a taxane-containing chemotherapy. Patients will be dosed every three weeks (Q3W) until four weeks afte
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
3. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
4. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
5. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
10. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
11. Tainted Chinese Food Ingredients First Discovered in 2005
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
(Date:12/22/2014)... Dec. 22, 2014 TWi Biotechnology, Inc., ... Allowance for AC-201, TWi Biotechnology,s lead drug candidate, ... China for patent application numbered ... acceptable salts, active metabolite for treatment of type ... of treatment using AC-201 for type II diabetes, ...
(Date:12/19/2014)... 2014 You,re visiting the dentist for what ... he or she says you need a root canal. ... may have several questions and feel apprehensive about your ... it,s nothing to worry about. The Pennsylvania Dental Association ... any anxiety the public may have surrounding this common ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Root Canals Have Become More Routine 2
... Inc. announced today that it has entered into ... to provide Otsuka with access to BioWa,s POTELLIGENT® ... of their antibody therapeutics with enhanced antibody-dependent cellular ... License was initiated in May, 2007 with Takeda ...
... PEAK Surgical, Inc. and Medtronic, Inc. (NYSE: MDT ... Technologies business at Medtronic exclusive rights for global distribution ... Adenoid) tissue dissection device for the ear, nose, and ... is a major step toward our goal of capturing ...
Cached Medicine Technology:BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear, Nose, and Throat Market 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear, Nose, and Throat Market 3
(Date:12/22/2014)... (PRWEB) December 22, 2014 The MedTech industry ... Inc, a wholly owned subsidiary of PartnerTech AB of Sweden, ... having recently achieved additional ISO Certification. , All signs point ... employment and the likelihood of a repeal of the excise ... . The industry is anticipating annual growth of 9.3% and ...
(Date:12/22/2014)... December 22, 2014 7,178 small business ... of Black Friday shopping and opted instead to join ... education company, for their 5th annual “Black Friday Boot ... just $7 to attend the 5 hour online training ... promptly donated to support two Central Texas based charities ...
(Date:12/22/2014)... Christmas is days away, and last minute gifts ... solution that will please: the Sublime Gift Card . ... $25 up to $350," says Kathy Heshelow, founder of ... wide array of skin care products and Skin Brushes." , ... , Gift delivery past shipping deadlines, or those last ...
(Date:12/22/2014)... OAK BROOK, Ill. (PRWEB) December 21, 2014 ... receive radiologist recommendations for chest computed tomography (CT) ... have clinically relevant findings, including cancer, according to ... Radiology. , Researchers said the findings show ... chest X-rays represent valuable contributions to patient care. ...
(Date:12/22/2014)... December 22, 2014 Parker & Sons, ... best in Arizona home contracting services reports a record ... its quality services in 2014. As a company that ... early 1970s, Parker and Sons is a business that ... company works side-by-side with other top quality companies in ...
Breaking Medicine News(10 mins):Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3
... 18 Taking Control of Your Diabetes,(TCOYD) announced ... national,research firm Yankelovich that found that more than ... think that excess weight has a positive effect ... overweight often contributes,to the development of diabetes, complicates ...
... Cross asks you to help save lives by donating ... is being held on Saturday, February 21, 2009 from ... Koerner of Sewell, New Jersey. To make an ... (1-800-448-3543). (Logo: http://www.newscom.com/cgi-bin/prnh/20081216/DC52619LOGO )Koerner is battling a ...
... contest for children K-5TULSA, Okla., Feb. 18 There ... sixth annual Be Smart--Don,t Start! storyboard contest, ... of tobacco use. Request free contest materials and information ... be postmarked by Feb. 27.Sponsored by the American Lung ...
... 2009 Takeda Pharmaceutical Company Limited and its wholly-owned ... the United States Food and Drug Administration (FDA) has ... the chronic management of hyperuricemia in patients with gout. ... option in more than 40 years for the more ...
... the journal Nature Genetics have for the ... heart attack and coronary heart disease. In one of ... kind, the Myocardial Infarction Genetics Consortium identified nine precise ... three of them newly discovered; the investigators said that ...
... to be an international leader in personalized medicine and ... of Canadians and to reap the benefits of job ... http://www.cmaj.ca/cgi/rapidpdf/cmaj.1090199 released online today in CMAJ ( Canadian ... based on an individual,s genetic and health needs, rather ...
Cached Medicine News:Health News:One in Five Augustans With Type 2 Diabetes Mistakenly Believe That Being Obese or Overweight Can Positively Impact Their Disease 2Health News:One in Five Augustans With Type 2 Diabetes Mistakenly Believe That Being Obese or Overweight Can Positively Impact Their Disease 3Health News:Blood Drive Held in Honor of Sewell, NJ Resident - Ellie Koerner 2Health News:Last Chance! Be Smart--Don't Start! Entries Due by Feb. 27 2Health News:FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout 2Health News:FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout 3Health News:New genomic markers associated with risk of heart disease and early heart attack 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: